Table 2.

Network meta-analysis of 11 targeted therapies plus fulvestrant for PFS and ORR

Placebo+ fulvestrant	2.84 (1.91–4.31)	3.62 (1.21–12.48)	1.62 (0.61–4.58)	1.80 (1.25–2.60)	1.27 (0.38–4.65)	2.52 (1.43–4.72)				0.22 (0.01–2.20)
0.55 (0.45–0.68)	Abemaciclib + fulvestrant	1.28 (0.39–4.59)	0.57 (0.20–1.73)	0.63 (0.37–1.10)	0.45 (0.13–1.72)	0.89 (0.44–1.86)				0.08 (0.00–0.80)
0.69 (0.41–1.14)	1.24 (0.72–2.16)	Dovitinib + fulvestrant	0.45 (0.09–2.03)	0.50 (0.14–1.59)	0.35 (0.06–1.94)	0.70 (0.18–2.45)				0.06 (0.00–0.77)
0.61 (0.40–0.93)	1.10 (0.69–1.74)	0.88 (0.45–1.71)	Everolimus+ fulvestrant	1.11 (0.37–3.20)	0.79 (0.16–3.92)	1.56 (0.48–4.91)				0.13 (0.00–1.67)
0.74 (0.66–0.84)	1.34 (1.06–1.71)	1.08 (0.64–1.83)	1.22 (0.79–1.88)	Buparlisib + fulvestrant	0.71 (0.20–2.67)	1.41 (0.71–2.90)				0.12 (0.00–1.27)
0.74 (0.52–1.06)	1.34 (0.89–2.03)	1.08 (0.58–1.99)	1.23 (0.70–2.13)	1.00 (0.69–1.46)	Pictilisib + fulvestrant	1.99 (0.49–7.80)				0.16 (0.00–2.31)
0.46 (0.36–0.59)	0.83 (0.60–1.16)	0.67 (0.38–1.18)	0.76 (0.47–1.23)	0.62 (0.47–0.82)	0.62 (0.40–0.96)	Palbociclib + fulvestrant				0.08 (0.00–0.92)
0.73 (0.49–1.09)	1.32 (0.84–2.07)	1.06 (0.56–2.07)	1.20 (0.68–2.14)	0.99 (0.65–1.49)	0.99 (0.58–1.68)	1.59 (0.99–2.52)	Bortezomib + fulvestrant
0.93 (0.64–1.36)	1.69 (1.10–2.62)	1.36 (0.72–2.56)	1.55 (0.89–2.69)	1.26 (0.85–1.88)	1.26 (0.76–2.11)	2.03 (1.29–3.18)	1.28 (0.74–2.22)	Vandetanib + fulvestrant
0.56 (0.43–0.74)	1.02 (0.72–1.45)	0.82 (0.46–1.47)	0.93 (0.57–1.54)	0.76 (0.56–1.03)	0.76 (0.49–1.19)	1.22 (0.84–1.78)	0.77 (0.47–1.26)	0.61 (0.38–0.96)	Ribociclib + fulvestrant
1.07 (0.44–2.63)	1.93 (0.77–4.90)	1.57 (0.56–4.47)	1.76 (0.66–4.82)	1.44 (0.58–3.60)	1.44 (0.55–3.84)	2.33 (0.90–5.92)	1.46 (0.55–3.92)	1.14 (0.43–3.05))	1.90 (0.74–4.80)	Selumetinib + fulvestrant

Notes: The results are presented as the HR and 95% Crl for PFS (lower left quarter) and as the OR and 95% CrI for ORR (upper right quarter). For PFS, HRs that are lower than 1 favor the row-defining treatment (ie, the HRs of ribociclib + fulvestrant compared with placebo + fulvestrant were 0.56, which favor ribociclib + fulvestrant treatment). For ORR, ORs that are higher than 1 favor the column-defining treatment (ie, the ORs of palbociclib + fulvestrant compared with placebo + fulvestrant were 2.52, which favor palbociclib + fulvestrant treatment). The significance of values in bold should be that the HRs/ORs and the corresponding 95% CrI have the significant difference.

Abbreviations: Crl, credible interval; ORR, objective response rate; PFS, progression-free survival.